Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00309907 · ClinicalTrials.gov registry record · Phase 2
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
A Phase 2 study of Juvenile Myelomonocytic Leukemia and Accelerated Phase Chronic Myelogenous Leukemia, sponsored by Children's Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 39
- Enrollment target
- 20
- Study locations
NCT00309907 is a Phase 2 study of Juvenile Myelomonocytic Leukemia and Accelerated Phase Chronic Myelogenous Leukemia that has completed, run by Children's Oncology Group. The registered enrollment target is 39 participants, below the 135-participant average among 11 other Juvenile Myelomonocytic Leukemia trials with a reported enrollment target (71% lower). The trial reports 20 study locations across 16 states.
The verdict
NCT00309907, a Phase 2 study of Juvenile Myelomonocytic Leukemia and Accelerated Phase Chronic Myelogenous Leukemia, has completed, sponsored by Children's Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 39 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase II trial is studying how well etanercept works in treating young patients with idiopathic pneumonia syndrome after undergoing a donor stem cell transplant. Etanercept may be effective in treating patients with idiopathic pneumonia syndrome after undergoing a donor stem cell transplant.
Conditions Studied
Interventions
- DRUG methylprednisolone
- BIOLOGICAL etanercept
Study Locations (20)
California
- Children's Oncology Group - Arcadia
- Loma Linda University Medical Center - Loma Linda
Indiana
- Indiana University Cancer Center - Indianapolis
- Indiana University Medical Center - Indianapolis
New York
- Columbia University Medical Center - New York
- New York Medical College - Valhalla
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
- Children's Hospital of Pittsburgh of UPMC - Pittsburgh
Alabama
- University of Alabama at Birmingham - Birmingham
Colorado
- Children's Hospital Colorado - Aurora
District of Columbia
- Children's National Medical Center - Washington D.C.
Florida
- All Children's Hospital - St. Petersburg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2006-04 |
| Est. Completion | 2011-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00309907
The ClinicalTrials.gov registry entry for NCT00309907 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 135-participant average among 11 other Juvenile Myelomonocytic Leukemia trials with a reported enrollment target (71% lower). The listed sponsor is Children's Oncology Group, which has 342 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Juvenile Myelomonocytic Leukemia appearing as the primary indexed condition, and to 2 interventions - of which methylprednisolone is the first listed.
NCT00309907 reports 20 study locations spanning 16 distinct geographic areas - top geographies include California, Indiana, New York.
Frequently Asked Questions
What is clinical trial NCT00309907 about?
NCT00309907 is a clinical study titled "Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant". This phase II trial is studying how well etanercept works in treating young patients with idiopathic pneumonia syndrome after undergoing a donor stem cell transplant. Etanercept may be effective in treating patients with idiopathic pneumonia syndrome after undergoing a donor stem cell transplant.
What is the current status of trial NCT00309907?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2006-04. Estimated completion is 2011-09.
What conditions does trial NCT00309907 study?
This clinical trial studies the following conditions: Juvenile Myelomonocytic Leukemia, Accelerated Phase Chronic Myelogenous Leukemia, de Novo Myelodysplastic Syndromes, Chronic Phase Chronic Myelogenous Leukemia, Childhood Acute Lymphoblastic Leukemia in Remission.
What interventions are being tested in trial NCT00309907?
The interventions under investigation include: methylprednisolone (DRUG), etanercept (BIOLOGICAL).
Who is sponsoring clinical trial NCT00309907?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00309907 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Juvenile Myelomonocytic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases
RECRUITING · Phase 2
-
Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia
ACTIVE NOT RECRUITING · Phase 2
-
Busulfan, Cyclophosphamide, and Melphalan or Busulfan and Fludarabine Phosphate Before Donor Hematopoietic Cell Transplant in Treating Younger Patients With Juvenile Myelomonocytic Leukemia
COMPLETED · Phase 2
-
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
RECRUITING · Phase 1
-
A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation
RECRUITING · Phase 1
-
CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT
RECRUITING · NA
Explore more on PlainTrial
Juvenile Myelomonocytic Leukemia
All registered trials for this condition
Accelerated Phase Chronic Myelogenous Leukemia
All registered trials for this condition
Alabama
All trials with a study site in Alabama
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.